The Serum Institute of Life Sciences will double its investment in one of Biocon Ltd’s units, giving it access to 100 million doses of vaccines annually along with the distribution rights to Serum’s vaccine portfolio, the Indian biopharma firm said on Tuesday. “Serum will not have an operational involvement but have a board seat”, says Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited.